|
|
Post by boytroy88 on Aug 11, 2017 7:05:40 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 11, 2017 7:38:52 GMT -5
MannKind (NASDAQ:MNKD) initiated with Buy rating and $4 (245% upside) price target by Maxim Group citing a capable management team focused on execution.
|
|
|
|
Post by peppy on Aug 11, 2017 7:50:47 GMT -5
MannKind (NASDAQ:MNKD) initiated with Buy rating and $4 (245% upside) price target by Maxim Group citing a capable management team focused on execution. and the post that started the thread. I wonder if a GS analyst will be on the next conference call. (plant) (Perhaps I need to change my meds.)
|
|
|
|
Post by op2778 on Aug 11, 2017 8:19:34 GMT -5
pump&dump.....yes....just like that
|
|
|
|
Post by centralcoastinvestor on Aug 11, 2017 8:28:47 GMT -5
I don't think the Maxim Group asked a question at the conference call. Yet the new coverage. Very nice. We may soon see more analysts coverage with more upgrades. It's about time.
|
|
|
|
Post by mnkdfann on Aug 11, 2017 8:34:25 GMT -5
I don't think the Maxim Group asked a question at the conference call. Yet the new coverage. Very nice. We may soon see more analysts coverage with more upgrades. It's about time. They did. Jason McCarthy - Maxim GRP - was the very first analyst to speak, and he had 2 or 3 questions. |
|
|
|
Post by centralcoastinvestor on Aug 11, 2017 8:40:42 GMT -5
I don't think the Maxim Group asked a question at the conference call. Yet the new coverage. Very nice. We may soon see more analysts coverage with more upgrades. It's about time. They did. Jason McCarthy - Maxim GRP - was the very first analyst to speak, and he had 2 or 3 questions. Thanks for the correction. I read through the transcript but obviously the Maxim name didn't stick. This is what happens when you get older, the memory goes first. |
|
|
|
Post by hillsave on Aug 11, 2017 9:03:06 GMT -5
MannKind (NASDAQ:MNKD) initiated with Buy rating and $4 (245% upside) price target by Maxim Group citing a capable management team focused on execution. Understatement about the management team. |
|
|
|
Post by peppy on Aug 11, 2017 9:09:58 GMT -5
Operator [Operator Instructions] And our first question comes from Jason McCarthy from Maxim GRP. Jason your line is now open. Jason McCarthy Hi guys congratulations on completing your first quarter with the new commercial team in place. Michael, can you talk a little bit more about the upcoming labeling change maybe give us a sense of the timing of the change and how you expect that to impact revenues in 2017 and going forward into 2018? Michael Castagna Sure thank you Jason. First the label change has a couple aspects to it and I think about it in three steps one there is the ability to articulate that the drug starts working within five minutes. The second part is we can articulate that it is faster than the competition. And the third is asking for a different category altogether. The important of these commercially really vary in terms of impact now in the second half of 2017 but as we go in 2018 and beyond. As repute to communicate we expect PDUFA approval by the end of Q3. So this will be a Q4 event in terms of launch and impact. Depending on which combination of those three activities happen really will depend on the upside in terms of the forecast and the accelerate growth that we expect post the label change. So for example if we were to get a different category that opens up a lot of the managed care access, if we takes that out of the bucket that we’re currently restricted in by the competition. So we don’t always control the buckets they’re consumed by the PBMs that drive 70% of the units in the country that really opens that window a little bit. It also dramatically could change Medicare Part D coverage. When it comes to the speed of onset saying we work within five minutes the reason that's important as we’re running these trials right now with DexCom and what you can see is within three dots on the DexCom you can see whether you got your appropriate dose we need to follow up the dose. Being able to have the clinical data that we kicked off coming out in time frame and read for us internally to know what the label change is going to be we are waiting to see a couple dots on their CGM which way did overshoot or undershoot for dosing in order to pull them back into time and range very quickly. We expect that the five minutes claim to be in there the data supports that and something we’re excited about. The other thing I can tell you is when we shared that PK/PD curve with the physician and asked them what does this mean to you the five-minute onset meant more to the physician than we expected in terms of just understanding the PK/PD is a product the speed of onset, getting out of body fast and all the things that come without backing of insulin and injecting. So that really gave them some confidence around how to mince with a drug and what they can communicate to the patient's. And then getting out of body faster and we know to make that claim is read our label today we say we get in the body faster, but we can't necessarily say we work any faster. And that’s been something that’s been bothering us since launch. And this to me is a very important label update is it really will allow to finally articulate the true profile of this product at least from the PK/PD. When you take that label change plus the work that Ray has been doing and his team that we’re really working on this one-two punch combination and when it comes to some of these things. I hope that answer your question Jason. Jason McCarthy No it does thank you very much. And just one more on international expansion you had mentioned Brazil earlier any plans for the Asian markets in particular China and how is MannKind thinking about those additional markets with the new commercial team in place. Michael Castagna So when we think about international markets, earlier this year when the commercial growth wasn't clear to everybody it’s was very hard to think about the right balance of a deal. Now that we have shown our first quarter behind us and its public we can start to show the early success of our commercial team so that the potential deal outside the U.S. can see that when we put the resources appropriately against this and the limited resource that we have and get the kind of growth we’re getting and continue that growth quarter-over-quarter. That will really help solidify some of the deals we’ve been working on. Obviously different markets around the world have dramatically different price points, but we are and have been and we’ll continue to talk to various partners in key markets. When we think of Japan you probably need a second study for Japan that’s typical and there's plenty of Japanese partners to consider for that one. When we think about India and China those are two great markets which have tremendous unmet need for example in India there is probably about 80 million patients with diabetes and their average A1C is about a 10th. So these people are under control and they need something that could be easier it really helps drive that and we have some innovative idea and I think about treatment with insulin in some of these markets. So we’ll continue to look at that and when I think about international markets their business opportunities but there also opportunities to help us turn our inventory faster as we think about scaling up the manufacturing plant insulin purchase commitments we have in the outer years this really helps turn some of that. And so we’ll continue to see nice offsets in terms of our fixed expenses but they’ll also help turn the inventory and some of those commitments that we have in the outer years. Operator seekingalpha.com/article/4096149-mannkinds-mnkd-ceo-michael-castagna-q2-2017-results-earnings-call-transcript?part=single |
|
|
|
Post by oldfishtowner on Aug 11, 2017 9:22:24 GMT -5
Any chance that Maxim and/or any of the other firms asking questions on the CC are working with MNKD/Greenhill to find investors for the preferred share issue and structure the terms of the shares?
|
|
|
|
Post by jred on Aug 11, 2017 9:22:25 GMT -5
I would be a little cautious with Kolbert's recommendation. Maxim group has an investment banking group with a client list of companies executing capital transactions similar to ones that Mike has been talking about as options. And there are a number of overlaps between Maxim's investment banking clients and Kolbert reports with buy ratings at multiples of current stock price - ADMP, INO, TROV, CTRV, CYTX, CTSO ...
This is just how the game is played. Still feel it's positive to have the buy rating and to have more analysts and their investment banking arms involved. Imo, afrezza has the science and performance behind it to carry the story. In addition to needing more patients and doctors aware of it, we also need more awareness in the investment community and analyst activity helps. For the long time followers of the story however, I would rely on more than just this report to buy more here. glta.
|
|
Tinkerbell
Researcher
Watcher of the Skies
Posts: 143
|
Post by Tinkerbell on Aug 11, 2017 9:30:12 GMT -5
MannKind (NASDAQ:MNKD) initiated with Buy rating and $4 (245% upside) price target by Maxim Group citing a capable management team focused on execution. Could not agree more. And this management team will get the label this insulin deserves as a first in class. That's the most critically important piece of the puzzle that needs to be addressed BEFORE regulatory submissions can begin outside of the USA. As far as I'm concerned, the company is on the cusp of achieving what bull investors have sought for a very, very, very long time. Clarity. I'm here to say that it is coming and by the end of September (perhaps sooner). Diabetics around the world will finally be able to achieve excellent time in range and be freed to live a happier, fuller and healthier life! Soon! |
|
|
|
Post by peppy on Aug 11, 2017 9:40:41 GMT -5
oldfishtower! man you are fast.
I read it, before the delete.
|
|
|
|
Post by babaoriley on Aug 11, 2017 9:48:12 GMT -5
Any chance that Maxim and/or any of the other firms asking questions on the CC are working with MNKD/Greenhill to find investors for the preferred share issue and structure the terms of the shares? Just what are you implying?  |
|
|
|
Post by peppy on Aug 11, 2017 9:50:23 GMT -5
Any chance that Maxim and/or any of the other firms asking questions on the CC are working with MNKD/Greenhill to find investors for the preferred share issue and structure the terms of the shares? Just what are you implying? I'll see you and raise you; That was my though exactly, even without knowing much about Maxim, just because, as you said, that is the way the game is played.
However, rather than saying be cautious with the analyst's recommendation, I look at it as the system at work. It makes me more confident the preferred shares will be placed.
I took the bait.
I like reading oldfishtower
|
|
